Indications and uses
First aid to help prevent infection and provide temporary relief in minor cuts, scrapes, and burns The Provision First Aid Line Manufactured for Provision Medical Products Palm Desert, CA 92211
First aid to help prevent infection and provide temporary relief in minor cuts, scrapes, and burns The Provision First Aid Line Manufactured for Provision Medical Products Palm Desert, CA 92211
adults & children 2 years & older: clean affected area, apply amount (equal to surface area of a tip of finger) on area 1-3 times daily. May be covered with a sterile bandage. children under 2: do not use, ask a doctor
TAMPER EVIDENT. DO NOT USE IF PACKET IS TORN OR CUT.
advanced Stops Pain and Prevents Infection for Cuts and Scrapes
BIOTIC-PLUS 0.5g
(in each gram)
Bacitracin zinc (400 units Bacitracin)
Neomycin sulfate (3.5 mg neomycin)
Polymyxin B sulfate (5000 units)
Lidocaine .40 mg
First Aid Antibiotic
First Aid Antibiotic
First Aid Antibiotic
Anesthetic
First aid to help prevent infection and provide temporary relief in minor cuts, scrapes, and burns
The Provision First Aid Line
Manufactured for Provision Medical Products Palm Desert, CA 92211
For external use only.
If ingested, contact a Poison Control Center directly.
white petrolatum
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1098397 | bacitracin 400 UNT / lidocaine 40 MG / neomycin 3.5 MG / polymyxin B 5000 UNT per GM Topical Ointment | PSN | 1 |
| 1098397 | bacitracin 0.4 UNT/MG / lidocaine 0.04 MG/MG / neomycin 0.0035 MG/MG / polymyxin B 5 UNT/MG Topical Ointment | SCD | 1 |
| 1098397 | bacitracin 400 UNT / lidocaine 40 MG / neomycin 3.5 MG / polymyxin B 5000 UNT per GM Topical Ointment | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| BACITRACIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| LIDOCAINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NEOMYCIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| POLYMYXIN B Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 69103-2400-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-9fd3-f424-e053-dadaa90a57ce | 0d3af5c2-e24a-4070-a059-5f7ceacb6540 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 69103-2400-1 | Biotic-Plus | 0.5 g in 1 POUCH | OINTMENT | 0.5 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 69103-2400 | BIOTIC-PLUS (BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, LIDOCAINE) OINTMENT [PROVISION MEDICAL] | 1 | Legacy NDC, 1 package rows | 20140728_0d3af5c2-e24a-4070-a059-5f7ceacb6540.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| bacitracin zinc | ACTIVE INGREDIENT | 89Y4M234ES | 1 | |
| lidocaine | ACTIVE INGREDIENT | 98PI200987 | 1 | |
| neomycin sulfate | ACTIVE INGREDIENT | 057Y626693 | 1 | |
| polymyxin b sulfate | ACTIVE INGREDIENT | 19371312D4 | 1 | |
| bacitracin | ACTIVE MOIETY | 58H6RWO52I | 1 | |
| lidocaine | ACTIVE MOIETY | 98PI200987 | 1 | |
| neomycin | ACTIVE MOIETY | I16QD7X297 | 1 | |
| polymyxin b | ACTIVE MOIETY | J2VZ07J96K | 1 | |
| petrolatum | INACTIVE INGREDIENT | 4T6H12BN9U | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69103-2400 | 69103-2400-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| bacitracin zinc | 89Y4M234ES | ACTIM |
| neomycin sulfate | 057Y626693 | ACTIM |
| polymyxin b sulfate | 19371312D4 | ACTIM |
| lidocaine | 98PI200987 | ACTIB |
| petrolatum | 4T6H12BN9U | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| petrolatum | PETROLATUM | 4T6H12BN9U | LIQUID / RESPIRATORY (INHALATION) | NA | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | TABLET, EXTENDED RELEASE / ORAL | 0.18 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CREAM, AUGMENTED / TOPICAL | 26 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | AEROSOL, FOAM / TOPICAL | 7.9 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CREAM / TOPICAL | 4213 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / TOPICAL | 7275 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT, AUGMENTED / TOPICAL | 81.94 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | TABLET / ORAL | 3.5 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / VAGINAL | 4084 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / AURICULAR (OTIC) | NA | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | SUPPOSITORY / VAGINAL | 27 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | OINTMENT / OPHTHALMIC | 88.4 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CAPSULE, EXTENDED RELEASE / ORAL | 0.07 mg | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | CAPSULE / VAGINAL | NA | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | EMULSION / TOPICAL | 7.8 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | LOTION / TOPICAL | 25 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | SOAP / TOPICAL | 0.85 %w/w | ||
| petrolatum | PETROLATUM | 4T6H12BN9U | SPONGE / TOPICAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 294cef14-6b97-4221-9f9e-13e9529194ff | 0d3af5c2-e24a-4070-a059-5f7ceacb6540 | 2014-07-24 | Warnings | 294cef14-6b97-4221-9f9e-13e9529194ff 0d3af5c2-e24a-4070-a059-5f7ceacb6540 |
Adverse event summaries are temporarily unavailable. Other product information remains available.